Tetrahydrobiopterin's Impact on Thinking Skills in Alzheimer's Disease
Tetrahydrobiopterin Effects on Cognitive Function in Alzheimer's Disease: Biochemical, Molecular and Cognitive Analysis
This project explores if a natural substance called tetrahydrobiopterin (BH4) can help improve memory and thinking in people with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11131131 on NIH RePORTER |
What this research studies
Alzheimer's disease causes severe memory loss and makes it hard to live independently, and new treatments are urgently needed. This project looks at repurposing an existing substance, tetrahydrobiopterin (BH4), which is important for brain chemicals and has been found to be low in people with Alzheimer's. Researchers are exploring how BH4 levels are linked to a specific gene and how increasing BH4 might improve cognitive function. The goal is to understand if BH4 could be a new way to help manage the symptoms of Alzheimer's disease.
Who could benefit from this research
Good fit: This research is focused on understanding Alzheimer's disease, particularly how a specific brain chemical and gene variations might affect cognitive abilities in patients.
Not a fit: Patients whose cognitive decline is not related to the specific biochemical pathways involving tetrahydrobiopterin may not directly benefit from this particular approach.
Why it matters
Potential benefit: If successful, this work could lead to a new treatment option that helps improve cognitive function and quality of life for individuals living with Alzheimer's disease.
How similar studies have performed: Preliminary studies have shown promising results with synthetic BH4 treatment in psychiatric patients, suggesting a potential for similar benefits in Alzheimer's disease.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Clelland, Catherine L — Columbia University Health Sciences
- Study coordinator: Clelland, Catherine L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.